BTHCF - Breathtec Biomedical, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.08
-0.01 (-8.05%)
At close: 3:36PM EDT
Stock chart is not supported by your current browser
Previous Close0.09
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume37,931
Market Cap2.122M
Beta (3Y Monthly)-0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that one of its lead compounds for Inflammatory Bowel Disease (“IBD”) NP-178 showed positive results in a recently completed study investigating its therapeutic effects in an ulcerative colitis mouse model. NP-178 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.

  • GlobeNewswire12 days ago

    Breathtec Provides Update on FAIMS Breathalyzer Development Program

    Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to report on the development of its Breathtec Disease Detection Breathalyzer (“V3”) prototype based on the  FAIMS (field asymmetric waveform ion mobility spectrometry) technology. Before the V3 prototype development phase is successfully completed, the device will need to achieve a number of performance characteristics including device sensitivity, precision and reproducibility in a laboratory setting.

  • GlobeNewswire16 days ago

    Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. NP-160 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.

  • GlobeNewswire24 days ago

    Breathtec Announces Closing of Private Placement

    Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Oct. 24, 2018 -- Breathtec Biomedical.

  • GlobeNewswire26 days ago

    Breathtec Announces Acquisition of Nash Pharmaceuticals

    Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce that further to its press release of October 9, 2018, it has completed the acquisition (the “Transaction”) of all of the issued and outstanding securities of Nash Pharmaceuticals Inc., a private British Columbia company, (“Nash Pharma”) pursuant to the terms of a share exchange agreement dated October 5, 2018 (the “Definitive Agreement”) among the Company, Nash Pharma and the securityholders of Nash Pharma. In consideration for the Transaction and pursuant to the terms of the Definitive Agreement, the Company issued an aggregate of 15,800,000 common shares in the capital of the Company (the “Payment Shares”) pro rata to the holders of Nash Pharma common shares at a deemed price of $0.24 per Payment Share.

  • GlobeNewswirelast month

    Breathtec to Complete Share Consolidation

    Breathtec Biomedical Inc. (BTH.CN) (BTH.CN) (BTI.F) (BTHCF) (the “Company”) is pleased to announce that further to its news release dated August 2, 2018, the Company will consolidate its common shares on a two (2) for one (1) basis and will begin trading on the Canadian Securities Exchange on a post-consolidated basis effective October 17, 2018 (the “Share Consolidation”). The Company currently has 57,897,356 common shares issued and outstanding. Following the Share Consolidation, the Company will have approximately 28,948,678 common shares issued and outstanding.

  • GlobeNewswirelast month

    Breathtec Announces Signing of Definitive Agreement to Acquire Nash Pharmaceuticals

    Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce that further to its press release of August 2, 2018, it has signed a share exchange agreement dated October 5, 2018 (the “Definitive Agreement”) among the Company, Nash Pharmaceuticals Inc. (“Nash Pharma”) and the securityholders of Nash Pharma to acquire all of the issued and outstanding securities of Nash Pharma (the “Transaction”). Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis, chronic kidney disease and inflammatory bowel disease.

  • GlobeNewswire2 months ago

    Breathtec to Participate in the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September 14-15

    Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) will be presenting at the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September 14-15.

  • GlobeNewswire2 months ago

    Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year

    Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to provide details on Nash Pharmaceutical’s (“Nash Pharma”) plans for the next 12 month period. Breathtec recently announced that it has signed a letter of intent (“LOI”) to acquire 100% of the shares of Nash Pharma. Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).